Skip to main content
Report this ad

See also:

FDA approves promising melanoma drug Keytruda

Many of the patients had significant long-lasting responses; therefore, the study was continued and the FDA granted the drug “breakthrough therapy” status
Many of the patients had significant long-lasting responses; therefore, the study was continued and the FDA granted the drug “breakthrough therapy” status
Robin Wulffson, MD
Report this ad